Patents by Inventor Martin Ryser
Martin Ryser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11419811Abstract: The present invention relates to a microorganism belonging to the group of lactic acid bacteria characterized in that it is capable of specifically binding to Streptococcus mutans, wherein the specific binding is (i) resistant to heat treatment; and/or (ii) resistant to protease treatment; and/or (iii) calcium-dependent; and/or (iv) formed within a pH range between 4.5 and 8.5; and/or (v) formed in the presence of saliva. Preferably, the specific binding can be assayed as follows: (a) growing said microorganism to stationary phase; (b) mixing said microorganism with Streptococcus mutans which has been grown to stationary phase; (c) incubating the mixture obtained in step (b) under conditions allowing the formation of aggregates of said microorganism and Streptococcus mutans and (d) detecting aggregates by the occurrence of a pellet.Type: GrantFiled: September 24, 2019Date of Patent: August 23, 2022Inventors: Bruno Kaesler, Rolf Knöll, Mewes Boettner, Eckhard Budde, Christine Lang, Martin Ryser, Markus Veen
-
Publication number: 20200085727Abstract: The present invention relates to a microorganism belonging to the group of lactic acid bacteria characterized in that it is capable of specifically binding to Streptococcus mutans, wherein the specific binding is (i) resistant to heat treatment; and/or (ii) resistant to protease treatment; and/or (iii) calcium-dependent; and/or (iv) formed within a pH range between 4.5 and 8.5; and/or (v) formed in the presence of saliva. Preferably, the specific binding can be assayed as follows: (a) growing said microorganism to stationary phase; (b) mixing said microorganism with Streptococcus mutans which has been grown to stationary phase; (c) incubating the mixture obtained in step (b) under conditions allowing the formation of aggregates of said microorganism and Streptococcus mutans and (d) detecting aggregates by the occurrence of a pellet.Type: ApplicationFiled: September 24, 2019Publication date: March 19, 2020Inventors: BRUNO KAESLER, Rolf KNÖLL, Mewes BOETTNER, Eckhard BUDDE, Christine LANG, Martin RYSER, Markus VEEN
-
Publication number: 20190381169Abstract: The present invention relates generally to a method for regulating immune reactions and test substances useful for same. Specifically, the method of the present invention relates to the modulation of the nerve growth factor receptor p75NTR, which is expressed by plasmacytoid dendritic cells. More specifically, the invention relates to a combination comprising at least one modulator of p75NTR signalling selected from a p75NTR antagonist or p75NTR agonist and at least one TLR receptor agonist selected from an agonist of TLR7 and/or TLR9. The invention further relates to the use of a combination of antagonists and agonists of p75NTR signalling and agonists of TLR7 and/or TLR9 as vaccine adjuvants and the invention provides vaccine compositions comprising antagonists and agonists of p75NTR signalling and agonists of TLR7 and/or TLR9.Type: ApplicationFiled: April 24, 2019Publication date: December 19, 2019Inventors: Sebastian Brenner, Martin Ryser, Cornelia Richter, Sebastian Thieme
-
Publication number: 20170258708Abstract: The present invention relates to a microorganism belonging to the group of lactic acid bacteria characterized in that it is capable of specifically binding to Streptococcus mutans, wherein the specific binding is (i) resistant to heat treatment; and/or (ii) resistant to protease treatment; and/or (iii) calcium-dependent; and/or (iv) formed within a pH range between 4.5 and 8.5; and/or (v) formed in the presence of saliva. Preferably, the specific binding can be assayed as follows: (a) growing said microorganism to stationary phase; (b) mixing said microorganism with Streptococcus mutans which has been grown to stationary phase; (c) incubating the mixture obtained in step (b) under conditions allowing the formation of aggregates of said microorganism and Streptococcus mutans and (d) detecting aggregates by the occurrence of a pellet.Type: ApplicationFiled: May 23, 2017Publication date: September 14, 2017Inventors: Bruno KAESLER, Rolf Knöll, Mewes Boettner, Eckhard Budde, Christine Lang, Martin Ryser, Markus Veen
-
Publication number: 20170189522Abstract: The present invention relates generally to a method for regulating immune reactions and test substances useful for same. Specifically, the method of the present invention relates to the modulation of the nerve growth factor receptor p75NTR, which is expressed by plasmacytoid dendritic cells. More specifically, the invention relates to a combination comprising at least one modulator of p75NTR signalling selected from a p75NTR antagonist or p75NTR agonist and at least one TLR receptor agonist selected from an agonist of TLR7 and/or TLR9. The invention further relates to the use of a combination of antagonists and agonists of p75NTR signalling and agonists of TLR7 and/or TLR9 as vaccine adjuvants and the invention provides vaccine compositions comprising antagonists and agonists of p75NTR signalling and agonists of TLR7 and/or TLR9.Type: ApplicationFiled: May 28, 2015Publication date: July 6, 2017Inventors: Sebastian BRENNER, Martin RYSER, Cornelia RICHTER, Sebastian THIEME
-
Publication number: 20120237454Abstract: The present invention relates to a microorganism belonging to the group of lactic acid bacteria capable of specifically binding to Streptococcus mutans, wherein the specific binding is (i) resistant to heat treatment; (ii) resistant to protease treatment; (iii) calcium-dependent; (iv) formed within a pH range between 4.5 and 8.5; and/or (v) formed in the presence of saliva. The present invention is also relates to an analog or fragment of the microorganism which is thermally inactivated or lyophilized, wherein the analog or fragment retains the capability of specifically binding to Streptococcus mutans. The invention further encompasses compositions and additives for food, feed or drinks comprising the microorganism or an analog or fragment thereof. Also provided is uses of the microorganism or an analog or fragment thereof for the preparation of an anticariogenic or pharmaceutical composition or anticariogenic food or feedstuff as well as methods for producing the compositions or food or feedstuff.Type: ApplicationFiled: May 2, 2012Publication date: September 20, 2012Applicant: BASF AktiengesellschaftInventors: Bruno Kaesler, Rolf Knöll, Mewes Boettner, Eckhard Budde, Christine Lang, Martin Ryser, Markus Veen
-
Patent number: 8192978Abstract: The present invention relates to a microorganism belonging to the group of lactic acid bacteria characterized in that it is capable of specifically binding to Streptococcus mutans, wherein the specific binding is (i) resistant to heat treatment; and/or (ii) resistant to protease treatment; and/or (iii) calcium-dependent; and/or (iv) formed within a pH range between 4.5 and 8.5; and/or (v) formed in the presence of saliva. Preferably, the specific binding can be assayed as follows: (a) growing said microorganism to stationary phase; (b) mixing said microorganism with Streptococcus mutans which has been grown to stationary phase; (c) incubating the mixture obtained in step (b) under conditions allowing the formation of aggregates of said microorganism and Streptococcus mutans and (d) detecting aggregates by the occurrence of a pellet.Type: GrantFiled: September 9, 2005Date of Patent: June 5, 2012Assignee: BASF AktiengesellschaftInventors: Bruno Kaesler, Rolf Knöll, Mewes Boettner, Eckhard Budde, Christine Lang, Martin Ryser, Markus Veen
-
Publication number: 20120020942Abstract: The invention concerns new isolated Lactobacillus cells, which are capable of aggregating Helicobacter pylori under culture conditions of the human digestive tract, in particular of the stomach, and to the uses of such cells.Type: ApplicationFiled: October 12, 2006Publication date: January 26, 2012Applicant: Organobalance, GMBHInventors: Mewes Bottner, Eckhard Budde, Christine Lang, Martin Ryser, Markus Veen
-
Patent number: 7846711Abstract: The invention concerns new isolated Lactobacillus cells, which are capable to aggregate Helicobacter pylori under culture conditions of the human digestive tract, in particular of the stomach, and to the uses of such cells.Type: GrantFiled: December 22, 2006Date of Patent: December 7, 2010Assignee: Organobalance GmbHInventors: Mewes Boettner, Eckhard Budde, Christine Lang, Martin Ryser, Markus Veen
-
Publication number: 20080193427Abstract: The present invention relates to a microorganism belonging to the group of lactic acid bacteria characterized in that it is capable of specifically binding to Streptococcus mutans, wherein the specific binding is (i) resistant to heat treatment; and/or (ii) resistant to protease treatment; and/or (iii) calcium-dependent; and/or (iv) formed within a pH range between 4.5 and 8.5; and/or (v) formed in the presence of saliva. Preferably, the specific binding can be assayed as follows: (a) growing said microorganism to stationary phase; (b) mixing said microorganism with Streptococcus mutans which has been grown to stationary phase; (c) incubating the mixture obtained in step (b) under conditions allowing the formation of aggregates of said microorganism and Streptococcus mutans and (d) detecting aggregates by the occurrence of a pellet.Type: ApplicationFiled: September 9, 2005Publication date: August 14, 2008Applicant: BASF AktiengesellschaftInventors: Bruno Kaesler, Rolf Knoll, Mewes Boettner, Eckhard Budde, Christine Lang, Martin Ryser, Markus Veen
-
Publication number: 20070148149Abstract: The invention concerns new isolated Lactobacillus cells, which are capable to aggregate Helicobacter pylori under culture conditions of the human digestive tract, in particular of the stomach, and to the uses of such cells.Type: ApplicationFiled: December 22, 2006Publication date: June 28, 2007Inventors: Mewes Boettner, Eckhard Budde, Christine Lang, Martin Ryser, Markus Veen